Should I buy or sell Ardelyx stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks .

What is Ardelyx's stock price target for 2024?

9 analysts have issued 1 year target prices for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's share price to reach $12.69 in the next twelve months. This suggests a possible upside of 97.0% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts .

How have ARDX shares performed in 2024?

Ardelyx's stock was trading at $6.20 on January 1st, 2024. Since then, ARDX stock has increased by 3.9% and is now trading at $6.44. View the best growth stocks for 2024 here .

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ARDX earnings forecast .

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $34.36 million during the quarter, compared to analysts' expectations of $34.26 million. Ardelyx had a negative trailing twelve-month return on equity of 43.57% and a negative net margin of 53.08%. The business's quarterly revenue was down 22.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.06 EPS.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) . Inspire Small/Mid Cap ETF (ISMD) .

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU) , Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , Rigel Pharmaceuticals (RIGL) , Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Corbus Pharmaceuticals (CRBP) , TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD) .

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.19%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include David P Rosenbaum , Elizabeth A Grammer , Jeffrey W Jacobs , Justin A Renz, Laura A Williams, Michael Raab , Robert Blanks , Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends .

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ARDX Stock Alerts

$6.44

-0.11 (-1.68%)

(As of 04/18/2024 ET)

Compare

Today's Range: $6.39
▼
$6.56
50-Day Range: $6.44
▼
$9.74
52-Week Range: $3.16
▼
$10.13

Volume: 3.73 million shs
Average Volume: 6.14 million shs
Market Capitalization: $1.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.69

Get Ardelyx alerts:

Ardelyx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.11 Rating Score
Upside/Downside: 97.0% Upside
$12.69 Price Target
Short Interest: Bearish
15.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.32
Upright™ Environmental Score
News Sentiment: 0.71
Based on 8 Articles This Week
Insider Trading: Selling Shares
$1.21 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.44) to $0.10 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.93 out of 5 stars

Medical Sector

283rd out of 918 stocks

Pharmaceutical Preparations Industry

114th out of 402 stocks

3.6

Analyst's Opinion

Consensus Rating
Ardelyx has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ardelyx has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
15.05% of the outstanding shares of Ardelyx have been sold short.
Short Interest Ratio / Days to Cover
Ardelyx has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in Ardelyx has recently decreased by 3.55%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ardelyx does not currently pay a dividend.
Dividend Growth
Ardelyx does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ardelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.
Environmental Sustainability
The Environmental Impact score for Ardelyx is -1.32.

2.6

News and Social Media Coverage

News Sentiment
Ardelyx has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Ardelyx this week, compared to 4 articles on an average week.
Search Interest
Only 25 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.
MarketBeat Follows
Only 19 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -34% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,208,524.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Ardelyx is held by insiders.
Percentage Held by Institutions
58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ardelyx are expected to grow in the coming year, from ($0.44) to $0.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ardelyx is -21.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ardelyx is -21.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ardelyx has a P/B Ratio of 8.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Ardelyx Stock (NASDAQ:ARDX)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARDX Stock News Headlines

April 18, 2024 | insidertrades.com

Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 7,500 Shares

April 3, 2024 | insidertrades.com

Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells $11,096.58 in Stock

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 23, 2024 | insidertrades.com

Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells $664,780.00 in Stock

April 19, 2024 | americanbankingnews.com

Michael Raab Sells 7,500 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock

April 19, 2024 | americanbankingnews.com

Ardelyx (NASDAQ:ARDX) PT Raised to $14.00

April 18, 2024 | investing.com

Ardelyx CEO Michael Raab sells $52,923 in company stock

April 18, 2024 | finance.yahoo.com

Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | finance.yahoo.com

Ardelyx, Inc. (ARDX) Interactive Stock Chart - Yahoo Finance

April 5, 2024 | markets.businessinsider.com

A Closer Look at 6 Analyst Recommendations For Ardelyx

April 2, 2024 | investorplace.com

The Millionaire's Shortcut: 3 Stocks to Transform Your Portfolio This Month

March 28, 2024 | globenewswire.com

Ardelyx, Inc. Reports Employment Inducement Grants

March 25, 2024 | globenewswire.com

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

March 21, 2024 | finance.yahoo.com

Institutional investors may overlook Ardelyx, Inc.'s (NASDAQ:ARDX) recent US$195m market cap drop as long-term gains remain positive

March 20, 2024 | ca.finance.yahoo.com

ARDX Apr 2024 7.500 put

March 20, 2024 | ca.finance.yahoo.com

ARDX Apr 2024 10.000 call

March 19, 2024 | money.usnews.com

Ardelyx Inc

March 16, 2024 | nasdaq.com

Guru Fundamental Report for ARDX

March 16, 2024 | investorplace.com

The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter

March 16, 2024 | ca.finance.yahoo.com

ARDX Mar 2024 11.000 call

March 16, 2024 | ca.finance.yahoo.com

ARDX Mar 2024 8.000 put

March 16, 2024 | ca.finance.yahoo.com

ARDX Mar 2024 8.000 call

March 15, 2024 | finance.yahoo.com

ARDX Mar 2024 8.500 call

March 15, 2024 | finance.yahoo.com

ARDX Mar 2024 10.000 put

March 13, 2024 | seekingalpha.com

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

March 12, 2024 | globenewswire.com

Ardelyx, Inc. Reports Employment Inducement Grants

See More Headlines

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARDX
CUSIP: N/A
CIK: 1437402
Web: www.ardelyx.com
Phone: (510) 745-1700
Fax: 510-745-0493
Employees: 267
Year Founded: 2007

Price Target and Rating

Average Stock Price Target: $12.69
High Stock Price Target: $15.00
Low Stock Price Target: $8.50
Potential Upside/Downside: +97.0%
Consensus Rating: Buy
Rating Score (0-4): 3.11
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,070,000.00
Net Margins: -53.08%
Pretax Margin: -52.65%
Return on Equity: -43.57%
Return on Assets: -26.03%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 4.88
Quick Ratio: 4.64

Sales & Book Value

Annual Sales: $124.46 million
Price / Sales: 12.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.72 per share
Price / Book: 8.94

Miscellaneous

Outstanding Shares: 232,690,000
Free Float: 219,888,000
Market Cap: $1.50 billion
Optionable: Optionable
Beta: 0.85

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Michael G. Raab (Age 59)
President, CEO & Director
Comp: $1.28M
Ms. Susan Rodriguez (Age 59)
Chief Commercial Officer
Comp: $760.77k
Dr. Laura A. Williams M.D. (Age 60)
M.P.H., Chief Medical Officer
Comp: $873.8k
Mr. Justin A. Renz CPA (Age 52)
MBA, Chief Financial & Operations Officer and Treasurer
Comp: $623.7k
Mr. Robert Felsch
Senior VP of Finance & Chief Accounting Officer
Ms. Elizabeth A. Grammer Esq. (Age 60)
Chief Legal & Administrative Officer and Secretary
Comp: $623.7k
Ms. Caitlin Lowie
Vice President of Corporate Communications & Investor Relations
Ms. Charon Spencer Sr.
Chief Human Resources Officer
Mr. David P. Rosenbaum (Age 63)
Chief Development Officer
Comp: $645.4k
Mr. Robert C. Blanks (Age 64)
Chief Regulatory Affairs & Quality Assurance Officer
Comp: $590.8k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.
What is Ardelyx's stock price target for 2024?: 9 analysts have issued 1 year target prices for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's share price to reach $12.69 in the next twelve months. This suggests a possible upside of 97.0% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.
How have ARDX shares performed in 2024?: Ardelyx's stock was trading at $6.20 on January 1st, 2024. Since then, ARDX stock has increased by 3.9% and is now trading at $6.44.
View the best growth stocks for 2024 here.
When is Ardelyx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARDX earnings forecast.
How were Ardelyx's earnings last quarter?: Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $34.36 million during the quarter, compared to analysts' expectations of $34.26 million. Ardelyx had a negative trailing twelve-month return on equity of 43.57% and a negative net margin of 53.08%. The business's quarterly revenue was down 22.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.06 EPS.

What ETFs hold Ardelyx's stock?: ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Inspire Small/Mid Cap ETF (ISMD).
What other stocks do shareholders of Ardelyx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).
Who are Ardelyx's major shareholders?: Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.19%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.
How do I buy shares of Ardelyx?: Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ardelyx (ARDX) Stock Price, News & Analysis

Ardelyx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ardelyx Stock (NASDAQ:ARDX)

ARDX Stock Price History

ARDX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ARDX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™